Nintedanib plus EGFR inhibitor for EGFR-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 70 years old.
- You have advanced (stage III or IV) non-small cell lung cancer with an EGFR gene mutation.
- You have tried and failed one first-line EGFR inhibitor medicine (like gefitinib, erlotinib, afatinib, or osimertinib).
- Your liver, kidneys, and bone marrow are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
This study tests a combination of two targeted therapies for non-small cell lung cancer that has continued to grow despite previous EGFR-targeted treatment. It aims to see if adding gumarontinib (a MET inhibitor) to another EGFR-targeted drug can control the cancer for longer.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.